The case of the miss­ing PD-L1: UCSF sleuths de­vise a new ‘tu­mor cell vac­cine’ and a check­point strat­e­gy that could sur­prise you

It will come as no sur­prise to any­one watch­ing the I/O mar­ket boom that PD-1/L1 drugs may be amaz­ing­ly ef­fec­tive, but for on­ly about 1 in 4 patents. In cer­tain types of can­cer, it’s much worse.

That 1 in 4 ra­tio has cre­at­ed a multi­bil­lion-dol­lar busi­ness — vir­tu­al­ly overnight in bio­phar­ma terms. But it has fo­cused an amaz­ing amount of at­ten­tion on the oth­er 3 who are miss­ing out.

Start­ing from that premise, a team of in­ves­ti­ga­tors at UCSF want­ed to find out why some can­cer cells had less of the PD-L1 pro­tein that are dis­played on the cell sur­face and used to cloak them­selves from an im­mune re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER